Articles

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era

Hematology-Oncology Unit, Bnai Zion Medical Center, Haifa, Israel;The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Hematology & Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel;The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Department of Hematology, AO Sant’Andrea, La Sapienza University, Rome, Italy
Hematology-Oncology Unit, Bnai Zion Medical Center, Haifa, Israel;The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Department of Hematology, AO Sant’Andrea, La Sapienza University, Rome, Italy
Division of Hematology, Fondazione IRCCS CàGranda, University of Milan, Milan, Italy
Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy
Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jeruslaem, Israel
Vol. 99 No. 1 (2014): January, 2014 https://doi.org/10.3324/haematol.2013.088161